PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Major Depressive Disorder

Psychiatric Times.
PODCAST 

New Medication Strategies for Non-responsive Depressed Patients

By Gerard Sanacora, MD, PhD | July 17, 2012

Dr Sancora discusses a novel class of drugs for depressed patients

Although there have been significant advances in the treatment of mood disorders, many limitations of current strategies remain—and a large proportion of patients never attain complete remission of symptoms.

A series of studies completed over the past 12 years suggest that a novel class of drugs that directly target the glutamatergic neurotransmitter system may produce rapid and robust antidepressant effects in patients who had previously not responded to the standard monoaminergic antidepressant medications.

(MORE: New Claims and Findings for Ketamine in Severe Depression)

In this companion podcast to his article, “Ketamine Induced Optimism,” Gerard Sanacora, MD, PhD, Professor of Psychiatry at the Yale University School of Medicine and Director of the Yale Depression Research Program in New Haven, Connecticut, discusses early-phase clinical studies that provide strong evidence that this novel class of drugs may advance our ability to treat mood disorders.

Novel Drugs for Mood Disorders

Novel Drugs for Mood Disorders

iTunes Subscribe to our podcasts

 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by mark holscher | August 22, 2012 7:54 AM EDT

i read an article on a trial of N acetyl cystiene at a dose of 1000mg bid in TRD patients over one month who had a >90 % response rate in those patients that was noted to wane when the supplement was stopped.
i checked with a pharmD and others about the safety of this supplement. there did not seem to be any obvious risk or reported negative reactions to this supplement.
i decided to try it on one of my most difficult patients who was currently on parnate and depakote for TRD and BP2 for 40 years. he was started on 600mg once daily then increased to 600mg bid in 1 week. i did not tell him what to expect but to call with any problems and to report back to me in 2 weeks for follow up. '
he reports a gradual improvemnt in most of his sypmtoms over the two weeks. namely he has bettter mood a calmer affect clearer thinking and less social sensitivity. he is still on the same dose and continues to do well. since he has only been om this for one month it will be interesting to see if the benefits will continue at this dose.
if he continues to do well i plan to try this on some of my other more difficult trd patients.
what a blessing if this supplement costing 15.00 a month could truely relieve some of these patients disabling symptoms and improve their quality of life. thank you.

More like this

Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants

New Medication Strategies for Non-responsive Depressed Patients

Ketamine, Cum Grano Salis

New Claims and Findings for Ketamine in Severe Depression






 
RELATED TOPICS

Bipolar disorder
Depressive disorders
Dysthymia
Mood disorders
Psychotic affective disorders
Major depressive disorder
Suicide prevention and assessment

 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
CME
Get CME for reading Psychiatric Times articles
Mood Disorders
Anxiety Disorders
Sleep Disorders
Psychopharmacology
Schizophrenia-Psychotic disorders
Cognitive Disorders
Substance Abuse
Medical Comorbidities
More Psychiatry CME


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Mdd
Evidence on Mdd
Guidelines on Mdd
Patient Education on Mdd
Clinical Trials on Mdd
Practical Articles on Mdd
Research and Reviews on Mdd
All "Mdd" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy